Canada markets closed

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1900-0.0200 (-1.65%)
At close: 04:00PM EDT
1.2353 +0.05 (+3.81%)
After hours: 04:43PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • A
    Alexander Denner will speak at the 13 D monitor active passive investor summit on october 18th. wonder if he will mention Amarin....
    so far no news from Sarissa.....
  • N
    Happy to say that I started taking Vascepa about 8 weeks ago when my triglyceride number was about 275ish. In full disclosure I should also say that since then I lost 15 pounds coming down from 230. Just had my blood work taken and my Triglycerides are down under 150 now. In addition, my blood sugar dropped nicely as well and my liver enzymes, which were high due to fatty liver disease dropped to the normal range. Much of the improvement may be attributed to weight loss, but I did not begin any exercise regimen. Could Vacsepa also contributed to the improved liver function? I know this point has arisen on this board in the past.

    Best of luck.

  • p
    Question: What is the main cause of death in Spain ?

    Answer: Cardiovascular diseases are the first cause of death in Spain, accounting for 33.71% of total deaths. Within this group, ischaemic heart disease is the first cause in men (22,923 deaths).

    Amarin arrives in Spain and focuses on cardiovascular residual risk.

    The North American company Amarin has landed in Spain and brings with it significant knowledge in the cardiovascular field backed by more than 10 years of accumulated investment in R&D and manufacturing in this area.

    As a result of this knowledge, Amarin has developed an innovative drug that "provides new hope for heart disease to stop being the main cause of death in Spain", explains the company. Vazkepa (ethyl icosapent) has obtained the support of the European Medicines Agency (EMA) and the European Commission for its commercialization of

    Vazkepa has obtained authorization for the treatment of residual cardiovascular risk, which until now current treatments did not address and represent a serious health and economic burden with 8% of health spending.
  • p
    Vascepa as a combo medicine for Diabetes/cholesterol treatment
  • D
    Finnally seeing some upside movement. Now just continue marching on and save lives with this product.
  • B
    If I was the CEO of a struggling, flailing company - I would be aggressively looking to strategize and pivot. And if I believed in the prospects of turning things around, I'd buy the stock, which would also send a message to the market. I don't have confidence that KM is doing anything more than passively sticking with his predecessor's playbook, waiting to appear at conferences, and collecting paychecks. It's actually shameful that he hasn't bought any stock. If he's not willing to invest at $1.10, he should be booted out. Hard to imagine that Denner is not as disillusioned as the rest of the shareholders - and he has the power to do something about it.
  • s
    Looking ahead, we continue to advance reimbursement discussions in multiple markets and have initial launch activities underway as we remain on track to deliver on our commitment to obtain reimbursement status and launch in up to six key European markets this year.

    So looks like this was a lie.
  • p
    Recent clinical insights with icosapent ethyl
  • s
    If Amarin’s Vascepa reduces plaque is there a role it may play in the treatment of Alzheimer’s ?
  • N
    I remember the days when there was a lot of camaraderie on this board and some genuine friendships developing, where investors were genuinely excited about the prospects of V and the company and the hugely positive impact on cardiovascular health this promised to bring. All washed away by a judicial decision which either should never have been allowed to happen and a far less arrogant AMRN should either have settled with the generics and never allowed this to get to court or should have done it’s homework properly and had all the bases covered. But we are where we are and c’est la vie as they say in French. A little humility never did anyone any harm, but thee wasn’t very much of this in existence at the time, unfortunately.

    I always maintained, due to the exceptional anti inflammatory properties V has displayed, that the icing on the cake, the crème de la crème, the holy grail, has been always been the treatment of dementia/Alzheimer’s. I still maintain that V will emerge in this space as a hugely effective treatment in slowing down the progress of this terribly destructive disease, which affects all families worldwide.

    So let’s keep the faith, why not , we’ve nothing to lose at this stage!
  • M
    Denner speaks at Activist convention Oct 6th in NY. He has to show cards one would think?
  • a
    Is Denner still in the game?
  • a
  • p
    It is very clear that this stock is being held back from going up waiting for the news....
  • J
    They had some interesting insights about AMRN on Definitely made me think twice about the company.
  • G
    Another brutal quarter comes to an end. Soon it will be our time. Stay well all
  • r
    MATCH the generic price, end all R&D spending, end all marketing, go completely bare bones and be done with it. They should have done this when they lost the appeal but they continued on. The go it alone strategy in Europe is a money pit, they need to find a partner, take whenever % they can get and stay the heck out of the marketing game.
  • p
    Don't know if this has been posted before but here's Amarin's sales partner HLS Th.

    HLS Therapeutics Announces Q2 Fiscal 2022 Financial Results
    TORONTO, Aug. 11, 2022

    Q2 2022 revenue of $15.5 million, Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million.

    Total Vascepa prescriptions grew 88% year-over-year, reflecting sequential growth of total and new Vascepa® prescriptions in Q2 2022 of 18% and 30%, respectively.

    2,400 physicians have prescribed Vascepa, up 131% year-over-year and 19% sequentially: 8,500 patients have taken Vascepa, up 107% year-over-year and 19% sequentially.
  • B
    Remember “BUY THE DIP”?